KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

被引：0

作者：

Kolinsky, Michael Paul

Gravis, Gwenaelle

Mourey, Loic

Piulats, Josep M.

Sridhar, Srikala S.

Romano, Emanuela

Berry, William R.

Gurney, Howard

Retz, Margitta

Appleman, Leonard Joseph

Boegemann, Martin

De Bono, Johann S.

Joshua, Anthony M.

Emmenegger, Urban

Conter, Henry Jacob

Laguerre, Brigitte

Wu, Helen

Schloss, Charles

Poehlein, Christian Heinrich

Yu, Evan Y.

机构：

[1] Cross Canc Inst, Edmonton, AB, Canada

[2] CLCC Inst Paoli Calmettes, Paris, France

[3] SIOG, Toulouse, France

[4] Catalan Inst Oncol, Barcelona, Spain

[5] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Inst Curie, Ctr Canc Immunotherapy, Paris, France

[7] Duke Canc Ctr Cary, Cary, NC USA

[8] Macquarie Univ Hosp, Sydney, NSW, Australia

[9] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany

[10] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[11] Univ Hosp Muenster, Munster, Germany

[12] Royal Marsden Hosp, London, England

[13] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[14] Sunnybrook Res Inst, Toronto, ON, Canada

[15] Univ Western Ontario, Brampton, ON, Canada

[16] Ctr Eugene Marquis, Rennes, France

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

103

引用

页数：2

共 50 条

[41] Assessment of quality of life (QOL), cognitive function and depression in a randomized phase II study of abiraterone acetate (ABI) plus prednisone (P) vs enzalutamide (ENZA) for metastatic castrate-resistant prostate cancer (mCRPC).
Khalaf, Daniel
Sunderland, Katherine
Eigl, Bernhard J.
Finch, Daygen L.
Oja, Conrad D.
Vergidis, Joanna
Parimi, Sunil
Zulfiqar, Muhammad
Gleave, Martin
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[42] Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study
Graff, J. N.
Burotto, M.
Fong, P. C.
Pook, D.
Zurawski, B.
Kopp, R. Manneh
Salinas, J. E.
Bylow, K.
Kramer, G.
Ratta, R.
Kwiatkowski, M.
Retz, M.
Kwak, C.
Arija, J. A. Arranz
Gurney, H. P.
Matsubara, N.
Liang, L. W.
Todoric, J.
Imai, K.
Stenzl, A.
ANNALS OF ONCOLOGY, 2023, 34 : S957 - S957
[43] Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC).
Dorff, Tanya B.
Groshen, Susan G.
Quinn, David I.
Goldkorn, Amir
Martel, Cynthia L.
Pinski, Jacek K.
Kuhn, Pater
Gross, Mitchell E.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[44] Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Yu, Evan Y.
Kolinsky, Michael P.
Berry, William R.
Retz, Margitta
Mourey, Loic
Piulats, Josep M.
Appleman, Leonard J.
Romano, Emanuela
Gravis, Gwenaelle
Gurney, Howard
Bogemann, Martin
Emmenegger, Urban
Joshua, Anthony M.
Linch, Mark
Sridhar, Srikala
Conter, Henry J.
Laguerre, Brigitte
Massard, Christophe
Li, Xin Tong
Schloss, Charles
Poehlein, Christian H.
de Bono, Johann S.
EUROPEAN UROLOGY, 2022, 82 (01) : 22 - 30
[45] Phase 1b/2 keynote-365 trial: Pembrolizumab (pembro) combination therapy in metastatic castration-resistant prostate cancer (mCRPC).
Yu, Evan Y.
Wu, Haiyan
Schloss, Charles
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[46] Phase I study of apalutamide (ARN) plus abiraterone acetate (AA), docetaxel (D) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
Molina, A. M.
Christos, P. J.
Whang, Y.
Nordquist, L.
Hackett, A. L.
Beltran, H.
Faltas, B.
Nanus, D.
Giannakakou, P.
Tagawa, S. T.
ANNALS OF ONCOLOGY, 2017, 28
[47] Pembrolizumab plus docetaxel and prednisone for enzalutamide- or abiraterone acetate-pretreated patients with metastatic castration-resistant prostate cancer: phase 3 KEYNOTE-921 study
Shore, Neal
Petrylak, Daniel
Bennamoun, Mostefa
Ratta, Raffaele
Piulats, Josep
Li, Ben
Schloss, Charles
Fizazi, Karim
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[48] Docetaxel (DOC) versus new androgen receptor-targeted agent (ART) in metastatic castrate-resistant prostate cancer (mCRPC) patients (pts) having received abiraterone (ABI) or enzalutamide (ENZA) as first-line (L1)
Broyelle, Antonin
Bimbai, Andre-Michel
Carnot, Aurelien
Pannier, Diane
Makhloufi, Samira
Ryckewaert, Thomas
Penel, Nicolas
Oudard, Stephane
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[49] Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC).
Mehra, Niven
Antonarakis, Emmanuel S.
Park, Se Hoon
Goh, Jeffrey C.
McDermott, Raymond S.
Gonzalez, Nuria Sala
Fong, Peter C. C.
Greil, Richard
De Santis, Maria
Yanez, Patricio Eduardo
Huang, Yi-Hsiu
Begbie, Stephen
Rey, Felipe
Kramer, Gero
Suzuki, Hiroyoshi
Saretsky, Todd L.
Ghate, Sameer R.
Cui, Yi
Kim, Jeri
Yu, Evan Y.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
[50] KEYNOTE-199 cohorts (C) 4 and 5: Phase II study of pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC).
Hoimes, Christopher J.
Graff, Julie N.
Tagawa, Scott T.
Hwang, Clara
Kilari, Deepak
Ten Tije, A. J.
Omlin, Aurelius
McDermott, Raymond S.
Vaishampayan, Ulka N.
Elliott, Tony
Gerritsen, Winald R.
Wu, Haiyan
Kim, Jeri
Schloss, Charles
De Bono, Johann S.
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →